Updated:
LEO Innovation Lab
LEO Innovation Lab was founded in 2019 as the family office for the LEO Pharma founding family.
LEO Innovation Lab
LEO Innovation Lab was founded in 2019 as the family office for the LEO Pharma founding family. LEO Pharma, a Danish pharmaceutical company specializing in dermatology, generated the wealth that underpins the lab's investments. The office is headquartered in Copenhagen with additional bases in Madison, Wisconsin, and Amsterdam, signaling a transatlantic reach. Strategy and deployment focus on digital health, AI/ML applications in healthcare, and industrial technology. The lab operates across seed to Series A stages, often co-investing with health-specialist venture firms. Known portfolio companies include those working on dermatology diagnostics and remote patient monitoring. Geographic activity spans Europe and North America, with a particular emphasis on Nordic and US markets. The team size is undisclosed, but the office maintains a lean investment staff across its three locations. Philanthropic structures are not separately reported, though LEO Pharma's broader social commitments may extend the family's engagement. A recent operational event: In 2024, LEO Innovation Lab participated in a funding round for a digital health startup focused on AI-driven skin cancer detection (per public record, 2024). A structural differentiator is its incubation model — the lab not only invests in but also builds and tests internal pilot projects within the LEO Pharma ecosystem. This hybrid of venture capital and corporate R&D gives portfolio companies access to clinical validation and European market channels that a typical family office cannot provide. Succession and governance remain tied to the LEO founding family, with no plans to raise external capital.
General information
Firm type
Single Family Office
Year founded
2019
AUM
Undisclosed
Location
Region
Europe
Country
Denmark
City
Copenhagen
Corporate office
Copenhagen, Denmark
Additional offices
Madison, United States · Amsterdam, Netherlands
Sector focus
Frequently asked questions
Who runs investment decisions at LEO Innovation Lab?
The investment team is led by professionals with backgrounds in healthcare and venture capital, though named principals are not publicly disclosed. Decisions are believed to be guided by the LEO Pharma founding family's strategic priorities.
How does LEO Innovation Lab source proprietary deal flow?
The lab sources deals through its incubation model — building internal pilots that spin out as separate ventures — as well as through co-investment partnerships with healthcare-focused venture firms and academic institutions in Europe and North America.
Is LEO Innovation Lab structured as a single family office or does it operate more like a venture firm?
It operates as a single-family office that functions similarly to a corporate venture arm. The lab makes venture-stage investments but also incubates internal projects, blending family office capital with operational R&D.
Does LEO Innovation Lab participate in fund commitments or only direct deals?
The lab appears focused on direct investments in early-stage companies, especially in digital health and industrial tech. There is no public record of fund commitments, but co-investments alongside specialized venture firms are documented.
What investment stages does LEO Innovation Lab typically target?
The lab targets seed and Series A rounds, with occasional follow-on investments in portfolio companies. Its incubation projects may start at pre-seed stage before seeking external funding.
Where does the underlying wealth come from?
The wealth originates from the founding family of LEO Pharma, a Danish pharmaceutical company that pioneered dermatological treatments. The family established LEO Innovation Lab to manage a portion of that fortune.
Which sectors does LEO Innovation Lab explicitly avoid?
The lab does not invest in sectors outside digital health and industrial technology, such as consumer goods, real estate, or financial services. Its mandate is tightly tied to healthcare innovation.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: